Newsroom

Newsroom

Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy

Literature
Read More

Personalised circulating cell-free tumour DNA analysis for detection of minimal residual disease and recurrence in patients with head and neck squamous cell carcinoma

Literature
Read More

Real time clinical utility of ctDNA genomic alterations in untreated patients with advanced NSCLC

Literature
Read More

Talking Cancer: Conversations with Trailblazers, Advocates, Patients, and Medical Ambassadors

Blog
Read More

NeoGenomics' Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application of its RaDaR™ MRD and InVisionFirst®-Lung Assays at the ESMO Congress 2021

Press Release
Read More

Precision Medicine

Blog
Read More

NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Press Release
Read More

NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Press Release
Read More

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients